Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 2,501–2,600 of 2,656
Aladhab, R. A. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20262782
Matteucci, A., Fusco, S. A. D., Bonanni, M., et al. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00637-7
“A total of 14 randomized placebo-controlled studies were selected [1–7 , 18– 24 ].”
Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study
Audrain, E., Lassen, P. B., Bellanné‐Chantelot, C., Vantyghem, M., Dupuis, H., Vidal-Trécan, T., Chevalier, N., Dubois‐Laforgue, D., Lamothe, S., Vatier, C., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71169
Yoshida, S., Iwatsubo, M., Nakamura, T., 小田, 牧., & Sakamaki, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71195
Jalil, S., Bari, K., Mumtaz, K., Ibrahim, A., Bhatti, T. K., Pothuraju, S., Adam, M., Magon, H. S., Duong, N. K., & Kwo, P. Y. (2026) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000001078
Interorgan Crosstalk in MASLD: A Narrative Review
Lonardo, A., & Weiskirchen, R. (2026) · Biomedicines · doi:10.3390/biomedicines14091949 · Cited by 1
Zhang, Z., Li, L., Yang, M., Chen, W., Xiao, L., Sun, L., & Agarwal, R. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag179
Urinary Biomarkers for the Risk Assessment and Management of Heart Failure: Pearls and Pitfalls
Roehm, B. A., Vaggar, Y., Grodin, J. L., & Toto, R. D. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00774-9
“Renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter-2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists can all decrease albuminuria [ 23 –27].”
Hsu, H.-C., Shih, L., Hou, Y., & Lu, K. (2026) · Biomolecules · doi:10.3390/biom16081155
Yi, Y., Park, S., Jeong, J. C., Na, K. Y., Chin, H. J., Yoo, S., Kim, S., Jung, C. H., Oh, J. S., Baek, G., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10180696/v1
Verdoia, M., Nardin, M., Ciliberti, G., Leverone, M., Paternoster, J., Faraguna, A., Barnoffi, E., Lorusso, D., Ciliberti, G., Piva, T., et al. (2026) · Diabetology · doi:10.3390/diabetology7080154
Molecular and clinical mechanisms of renal protection by SGLT2 inhibitors: a comprehensive review
Hocher, B., Hocher, C., & Elitok, S. (2026) · Current Opinion in Physiology · doi:10.1016/j.cophys.2026.100989
Kanbay, M., Mizrak, B., ÇIĞ, E., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113496
Safety and Tolerability of SGLT2 Inhibitors
Muskiet, M. H. A., van Raalte, D. H., & Smits, M. M. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_826
Kjær, T. K., Lindhardt, M. K., Riis, A. H., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101497
“7,8,16 Sensitivity analysis Probabilistic sensitivity analyses (PSAs) were made for all subgroups to evaluate the robustness of the ICERs.”
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
Briggs, A. H., Kohli-Lynch, C. N., Levy, A. R., Lin, Z., Chatterjee, S., Donato, B. M. K., & Kovesdy, C. P. (2026) · PharmacoEconomics - Open · doi:10.1007/s41669-026-00649-8
SGLT2 Inhibitors and Outcomes in Elderly Patients With Chronic Kidney Disease: A Narrative Review
Zhang, F., Dong, S., Zhong, Y., & Zhang, X. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71174
Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D
Halliburton, S., Herber, E., Pantalone, K. M., Parker, M., & Soric, A. (2026) · Endocrine Connections · doi:10.1530/ec-25-0785
Polyakova, E. A., & Zaslavskaya, E. L. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-7061
“…описан именно в ис-следованиях статинов, однако аналогичное явление наблюдалось и при использовании антигипертензив-ных препаратов, а также пероральных сахароснижа-ющих средств, что свидетельствует об общности эф-фектов, не ограниченных действием отдельных клас-сов лекарственных препаратов [12-14].”
Lee, S. Y., Kim, S. M., & Song, Y. B. (2026) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2026.0011
Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design
Zoccali, C., & Levin, A. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag176
Dai, D., Martins, I., Daneshgar, N., Gao, M., Rodriguez, B., Khan, M. M., Hinton, A. O., Jr., Crawford, P. A., & Grueter, C. E. (2026) · Cells · doi:10.3390/cells15161478
“Recent clinical trials have revealed a paradigm shift in their clinical utility, demonstrating robust cardio-protective and nephroprotective [2] benefits that extend beyond glycemic control.”
Mahmood, S. A., Al-Mukhtar, E. J., & AL-Saffar, Y. R. (2026) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_139_23
Banerjee, M., Basu, M., Mukhopadhyay, P., & Ghosh, S. K. (2026) · Endocrine · doi:10.1007/s12020-026-04752-y
Finerenone Plus Empagliflozin: How Low Can We Go, and How Much Does Blood Pressure Matter?
Zoccali, C., & Mallamaci, F. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.27364
Li, L., Lui, D. T. W., Fong, C. H.-Y., Mak, J. H., Cheung, C. Y. Y., Xu, A., Tan, K. C. B., Tse, H., Woo, J., Lam, T., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044588
Tong, X., Wang, B., Gao, F., Zhong, A., Fan, W., Zhang, Y., & Huang, W.-Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118382
Singh, B., Yaylaci, F., Ali, H. M., Baweja, R., Suarez, M. L. G., & Baweja, R. K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122407
Naik, B., Shrimant, Y., Patro, D., et al. (2026) · Cureus · doi:10.7759/cureus.115001
“Similar renoprotective benefits associated with empagliflozin have been consistently demonstrated in major clinical trials and real-world studies evaluating SGLT2 inhibitor-based therapies among patients with T2DM and CKD [14,17,20-22].”
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
Shang, Y., Wang, Y., Luo, Q., He, R., Wang, S., Wang, B., Lin, W., Zhou, Y., He, Q., He, Q., et al. (2026) · Seminars in Immunopathology · doi:10.1007/s00281-026-01083-y
Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study
Pei, J., Sun, X., Xu, X., Bai, P., Huang, R., Zhang, J., Chen, X., Yao, L., Shao, L., & Li, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2681246
Liu, Y., Gao, L., Xu, H., Zhou, Y., Chen, Y., Wang, L., Zhao, F., Pan, T., & Liu, Z. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2703925
“…and nonsteroidal mineralocorticoid receptor antagonists (nsMras), such as finerenone, for selected patients with diabetic CKD and albuminuria [3,4]. while these medications are effective in reducing intraglomerular pressure and proteinuria, intervention in the intracellular fibrosis signaling…”
Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors
Ni, H., Piggott, S., Festa, M. C., Faruque, L. I., & Cherney, D. Z. I. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2723583
“Dedicated kidney outcome trials, including CREDENCE and SCORED in adults with type 2 diabetes (T2D) and CKD, and DAPA-CKD and EMPA-KIDNEY in CKD populations with and without T2D, showed substantial reductions in kidney disease progression, HF and cardiovascular mortality [18– 21].”
Lido, P., Ratti, S., Ronchetti, C., Infante, M., Tesauro, M., Mannucci, P. M., Staszewsky, L. I., Nobili, A., Tettamanti, M., REPOSI Investigators, et al. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04495-8
Mallek, W., Wróblewska-Schmude, A., Lesner, A., Piwkowska, A., & Wysocka, M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118396
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
Chen, T., & Tsai, S. (2026) · Science Progress · doi:10.1177/00368504261484176
Casper, J., Doricic, J., Tian, Z., Willerding, J. M., Glammeier, M., Melk, A., Schmidt-Ott, K. M., & Schmidt, B. M. W. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag198
Gobaru, M., Hasuzawa, N., Kurinami, N., Wada, N., Wang, L., Nagayama, A., Ashida, K., Moriyama, Y., Jinnouchi, H., & Nomura, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1924744
Phongphithakchai, A., Wongna, K., Netphakdee, R., Klangbud, W. K., Thanasai, J., Kawakami, F., & Chatatikun, M. (2026) · Medical Sciences · doi:10.3390/medsci14050521 · Cited by 1
Zhou, Z., Zhang, Y., Xu, K., Wang, C., Fan, Z., & Zhang, F. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01713-z
Raposeiras‐Roubín, S., Gonzalez-Manzanares, R., Amat-Santos, I. J., Melendo‐Viu, M., Dobarro, D., López‐Otero, D., Franco, L. N., Gheorge, L., y, J. S.-S., Carlos, B. Z., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag242
Nikolov, D., Todorova, G. V., Simova, I. I., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10821134/v1
Hu, H., Hou, S., Chen, W., & Hu, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118405
Durma, A. C., Blicharska, M., & Czupryniak, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01913-0 · Cited by 1
Sharma, A., Sharma, B., Vamaraju, D. S., & Ajay, A. K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1923548
Acute coronary syndrome: Non-ST-segment elevation myocardial infarction, emerging perspective 2026
Dhananiwala, A., & Bhandari, S. (2026) · Journal of current cardiology. · doi:10.4103/jcc.jcc_27_26
Prospects for the use of new antidiabetic drugs in rheumatology
Nasonov, E. L., Shestakova, M. V., Kondratyeva, L. V., & Елисеев, М. С. (2026) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2026-315-334 · Cited by 1
Peres, R. A. S., Pinto-Figueiredo, A. C., Teixeira¹, D. E., Silva-Aguiar, R. P., Alves, S. A. S., SERPA, G. B., Gomes, C. P., Dias, W. B., Pinheiro, A. A. S., & Caruso‐Neves, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1899334
LeBleu, G., & Haj, F. G. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01282-7
Yan, H., Wang, W., Wu, W., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001201
Nahar, S., Haque, S. N., & Halder, S. (2026) · Exploration of Cardiology · doi:10.37349/ec.2026.1012120
Bartram, M. P., Cukoski, S., Scherrer, P., & Müller, R.-U. (2026) · Nephrologie aktuell · doi:10.1055/a-2835-9943
Bi, S., Li, D., Du, J., Li, W., Yang, X., Yao, Z., Zhang, Y., Zhang, W., & Yao, Z. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm48719
SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A/20-HETE pathway in the kidney
Zhou, Z., Hang, W., Zhao, R., Jiang, J., Wu, J., & Wang, D. W. (2026) · Bioscience Reports · doi:10.1042/bsr20260150
Promoting Healthy Aging with Gerotherapeutic Medications
Kwon, O. S., & Al‐Naggar, I. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-21928-2_24
Guzmán, G. E., Figueroa, F., Granados, S., Arias‐Valderrama, O., Giraldo, J., & Durán, C. E. (2026) · Medicine · doi:10.1097/md.0000000000050385
“[12] Recent multicenter studies have explored SGLT2i in kidney transplant recipients (KTRs).”
Nenova, D. D., Yankov, Y. G., & Chausheva, G. M. (2026) · Cureus · doi:10.7759/cureus.115840
“These events were generally mild and infrequently resulted in treatment discontinuation [3-7 , 15-22 15-22 ].”
InfluentialNaaman, M., Fisher-Negev, T., Aharon‐Hananel, G., Harel, T., & Cahn, A. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70226
“They have demonstrated cardiovascular and renal benefits in patients with and without diabetes [2–8].”
Traditional Chinese Medicine Research in Chronic Kidney Disease: Challenges and Future Perspectives
Li, X., Zhang, Z., He, C., & Zhong, Y. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151718
Yamanouchi, M., Sawa, N., Furuichi, K., & Wada, T. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101516
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.51.90.102
Renal Outcomes in Hereditary Fibrinogen A Alpha-Chain Amyloidosis
Carruthers, J. E., Rauf, M. U., Goodman, H. J. B., Petrie, A., Rowczenio, D. M., Taylor, G. W., Canetti, D., Fernandes, R., Gilbertson, J. A., Martinez–Naharro, A., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107076
Sun, D., Wang, X., Wang, H., Shen, Z., Meng, X., & Zhou, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933732
Why wait? Early combination therapy in diabetic kidney disease: lessons from CONFIDENCE
Ponlot, E., & Jadoul, M. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.132
Khogalee, M., Mohamed, S., Otim, M. E., Basher, M., Mumtaz, M., Thaslim, S., & Houni, A. E. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.08.004
Liu, H., Sun, F., Ma, J., et al. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.09.010
Diabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes
Hansrivijit, P., Patorno, E., Tesfaye, H., Wexler, D. J., Roh, M., & Paik, J. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101518
Sriperumbuduri, S., Khan, R. W., Aftab, S., Hiremath, S. S., Dixon, D. L., & Gupta, G. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag111
Branigan, P., Duong, V. N. Y., & Branigan, S. (2026) · Cureus · doi:10.7759/cureus.116039
“CREDENCE showed kidney protection with canagliflozin in patients with T2DM and nephropathy, while DAPA-CKD and EMPA-KIDNEY expanded the evidence for SGLT2 inhibition across broader CKD populations [12-14].”
Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection
Wise, M. L., & Alli, A. A. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030068
“Similarly, the EMPA-KIDNEY trial demonstrated that empagliflozin reduced progression of kidney disease and cardiovascular death across a broad CKD population, including non-diabetic patients [51].”
Giannini, C., Shih, W. V., Grewing, A., Chan, M., & Gist, K. M. (2026) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-026-00390-8
“The EMPA-Kidney study in adults with CKD demonstrated that SGLT2i significantly reduced the progression of CKD and the risk of heart failure [67].”
Iron, ESA, and HIF-Inhibitors: Are There Other Opportunities to Improve Anemia of CKD?
Bonomini, M., Vecchio, L. D., Minutolo, R., Sirolli, V., & Locatelli, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187070
Stefanska, C., Chung, R., Ramjaun, S., Jin, D., Doherty, C., McCafferty, K., & Seidu, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71298
Prognoseverbesserung bei Dialysepatienten: Was wirklich einen Unterschied macht
Mandel, S., Kraft, L., Schanz, M., & Latus, J. (2026) · Die Nephrologie · doi:10.1007/s11560-026-00950-x · Cited by 1
Clinical Evidence of Cardioprotective Effects of SGLT2 Inhibitors
Usman, M. S., Verma, S., & Pandey, A. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_827
Vega, D. S., Oskoui, E., & Siskind, L. J. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_853
Macrophage–Fibroblast Crosstalk in Kidney Injury: A Narrative Review
Qiang, P., Han, L., Lv, R., Dong, Z., Ma, T., Wang, X., & Xu, Q. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188173
“EMPA-KIDNEY enrolled 6609 patients with CKD at high risk of progression; empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28%, with consistent findings in participants with and without diabetes [131].”
Кузина, И. А., Эдуардовна, Т. М., & Петунина, Н. А. (2026) · Axis of endocrinology · doi:10.46393/30337380_2026_2_4-10
Okhovat, V., Lybeshari, K., Cubeddu, L. X., & Hale, G. M. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00829-1
Eddy, E., Long, B., Sandei, T., & Meyer, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00651-5
El‐Kassas, M., Awad, A., AlNaamani, K. M., Alswat, K., & Elzouki, A.-N. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.57
Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE
Cherney, D. Z. I., Yi, T. W., Heerspink, H. J. L., Ji, L., McGill, J. B., Rossing, P., Tuttle, K. R., Bech, J. N., Fiorina, P., Power, A., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107083
Marqués-Vidas, M., Quiroga, B., Portolés, J. M., Ortíz, A., Fernández‐Fernández, B., Horrillo, A. S., Soler, M. J., García-Carro, C., Morales, E., & Bajo, M. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187201
Joya, T. E. S., Jiménez, L. L. M., Teran, O. S. P., & Rodriguez, A. P. (2026) · VitalyScience Revista Científica Multidisciplinaria · doi:10.56519/mjmh0g15
Somaili, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187185
li, W., Zheng, J., Lv, W., xu, L., Si, K., Liu, Y., Hu, S., Wu, S., Dai, Y., Dong, Q., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10749649/v1
Yimsuk, I., Vongsaroj, A., Suebchompoo, P., Attarungrod, A., Yamba, A., & Paiboonvong, T. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030035
Beyond haemodynamics: Do SGLT2 inhibitors protect the podocyte?
Kumar, A. V., & Wong, E. T. Y. (2026) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2026555
Bibi, M., Arshad, R., Kousar, S., Gul-e-Maryam, Iqbal, J., Fatima, A., Siddique, R., & Ashfaq, A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108957
Ayusso, L. L., Girol, A. P., Neto, L. M., Gomes, I., & Burdmann, E. A. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0349pt
Ayusso, L. L., Girol, A. P., Neto, L. M., Gomes, I., & Burdmann, E. A. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0349en
Mishra, A., mishra, P., Bajaj, S., Kalra, P., Mishra, V., Bhat, S., Patni, B., Abichandani, V. K., Farishta, F., Aggarwal, V., et al. (2026) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2026.100865
Ji, K., Zhang, D., Zhao, Y., Zeng, Z., Jiang, M., & Zhang, J. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101793
Shinagawa, N., Okada, H., Hironaka, J., Yamamoto, S., Yoneda, M., Kawai, S., Saijo, Y., Katayama, T., Nakajima, H., 貴志, 明., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70445
Nassiri, S., Handoko, M. L., van de Bovenkamp, A. A., van Empel, V. P. M., van Raalte, D. H., & Eringa, E. C. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10671-x
“…SGLT2i on the primary composite outcome of reduction of kidney failure, cardiovascular death, and hospitalization for HF were evident in both patients with and without diabetes, with RRR ranging from 29% to 36% in patients with diabetes and from 18% to 50% in those with - out diabetes [43, 44, 46].”
Tian Guang, L. E. I., Zheng, B., Pang, Y., Zhao, J., Wang, Y., Wang, M., & Zhao, W. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119938
Abdelnabi, M., Pham, H. N., Ibrahim, R., Allam, M., Pathangey, G., Tan, M. C., Lee, K., Fortuin, F. D., Alsidawi, S., Ayoub, C., et al. (2026) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001936
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.